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Abstract
Objective—Innovative screening methods such as self-testing for human papillomavirus (HPV) 
may alleviate barriers to cervical cancer screening. The purpose of this exploratory study was to 
determine whether Appalachian Kentucky women would be amenable to self-collecting a cervico-
vaginal specimen for HPV testing.
Methods—Women aged 30–64 who were overdue for guideline-recommended cervical cancer 
screening were recruited from a primary care clinic in southeastern Kentucky. The women were 
asked to self-collect a specimen, using a cervico-vaginal brush, based on verbal and printed 
directions provided by a research nurse. All study participants, regardless of laboratory-confirmed 
HPV status, received the same counseling on the importance of cervical cancer screening and 
offered navigation to follow-up Pap testing at the local health department.
Results—Thirty-one women were approached and recruited to participate in the study, indicating 
a 100% acceptance rate of HPV self-testing. Of the 31 women, 26 tested negative for high-risk 
HPV and five tested positive. All of the women with negative results declined nurse navigation to 
Pap testing, whereas four of the five women with positive results accepted nurse navigation and 
received subsequent Pap smear screenings (all results were normal).
Conclusions—Among this sample of Appalachian Kentucky women, self-collecting a cervico-
vaginal specimen for HPV testing was highly acceptable. This exploratory study provides impetus 
for larger studies among high-risk, medically underserved women in rural communities. Tailoring 
alternative cancer screening strategies to meet the complex needs of rural women is likely to lead 
to reductions in cervical cancer incidence and mortality among this vulnerable population.
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Introduction
Despite being one of the few cancers that is theoretically 100% preventable, about 12,000 
new cases of invasive cervical cancer (ICC) are diagnosed annually in the U.S. [1]. 
According to the National Cancer Institute, in 2009, the incidence rate of ICC was 7.9 per 
100,000 women [2], an endemic level that remains an intractable challenge to public health, 
particularly in rural communities. Women who reside in rural areas have consistently higher 
incidence and mortality rates of this disease compared to their urban counterparts [3]. More 
specifically, residents of Appalachia have been disproportionately affected by this 
malignancy [4–7]. Even within Appalachia, certain geographical areas are more heavily 
burdened with ICC. For example, higher mortality rates have been found in the Appalachian 
region of Kentucky compared to Appalachian regions of other states [5,7,8]. The Kentucky 
Cancer Registry (2006–2010) reports an increased age-adjusted ICC mortality rate in 
Appalachian counties (9.76 per 100,000) compared to non-Appalachian counties (8.47 per 
100,000) within the state [9].
Contributing to the increased burden of ICC in rural Appalachia is lower Papanicolaou (Pap) 
testing rates [10–12]. In 2010, the majority of Appalachian Kentucky counties reported 
lower rates of women aged 18 and over receiving a Pap test within the past 3 years (74.3%–
78.3%) compared to state (80.9%) and national (81.1%) estimates [13]. Lower rates of Pap 
testing among this population are concerning because routine screening for cervical 
abnormalities, combined with effective treatment, has been shown to dramatically decrease 
the risk of developing ICC. For example, approximately 60% of all new ICC cases in the 
U.S. occur among women who are rarely or never screened [14]. Low Pap testing rates 
among rural, Appalachian women are associated with various factors, including older age, 
lack of health insurance, transportation barriers, lack of childcare, tobacco use, and lower 
levels of income and education [10–12,15–17]. Furthermore, community-level healthcare 
provider shortages, lack of a medical home, travel distances and clinic hours, 
embarrassment, discomfort with male providers, and lack of continuity of care influence 
Appalachian women's decisions to obtain Pap tests [10,11,15–19].
Due to the numerous barriers that prevent Appalachian women from obtaining routine Pap 
testing, the need for a convenient cervical cancer screening method is apparent. The high-
risk (oncogenic) human papillomavirus (HR-HPV) test [20,21] is a highly efficient method 
of screening that women may be able to perform themselves in the privacy of their home or 
other private location, thereby averting clinic-based barriers to initial screening [22]. A 
recent review of the literature revealed that self-collected cervico-vaginal samples for high-
risk HPV testing are comparable to physician-collected samples in terms of accuracy in 
detecting cervical intraepithelial neoplasia grade 2 (CIN2) or higher [23].
Given the advent of self-collection methods as an initial screening option for ICC, an 
important research question involves acceptability of self-collection among various 
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populations of at-risk women. To date, studies have largely established high rates of 
reported acceptance for self-administered cervico-vaginal specimen collection among 
various populations of women [24,25]. A review conducted in 2011 found that studies 
reported acceptance rates of 75–93% [25]. Furthermore, studies have shown high 
acceptability among women living in low-resource settings both domestically and abroad 
[26–30]. However, the majority of studies have been conducted in urban areas; the question 
of acceptability for self-collected methods for cervical cancer screening has yet to be 
addressed among medically underserved women living in rural Appalachia.
Accordingly, the purpose of this exploratory study was to determine whether Appalachian 
Kentucky women would be amenable to self-collecting a cervico-vaginal specimen for HPV 
testing. A secondary purpose of the study was to implement and track the results of a patient 
counseling and navigation intervention promoting guideline-recommended cervical cancer 
Pap smear screening among all women participating in the study.
Methods
Study sample
Recruitment took place at a free primary care clinic in southeastern Kentucky. The clinic 
provides care to residents of some of the poorest and most medically underserved counties 
in the U.S. [31,32]. Many of the patients are without health insurance. An advanced practice 
registered nurse (APRN) employed by the University of Kentucky Rural Cancer Prevention 
Center recruited potential study participants at the clinic on six separate days in November 
2011. The nurse answered questions about the study, screened women for study 
participation, obtained informed consent and baseline data, and provided both verbal and 
visual self-collection directions. Women were eligible to be in the study if they were 
between the ages of 30 and 64, were not pregnant, reported not having a Pap test in the past 
four years, and had never tested positive for HPV infection. Participants were also asked to 
complete a HIPAA release form, which provided researchers access to specific medical 
information (i.e., follow-up Pap smear results) needed for study evaluation.
Data collection
After provision of informed consent, women completed a brief, self-administered 
questionnaire written at a sixth-grade reading level. Items assessed socio-demographics, 
smoking status, and sexual behaviors, including number of lifetime male sex partners, 
number of male sex partners within the past 12 months, and knowledge of whether their 
male partners had concurrent sex partners. Women also provided information about their 
past experiences with Pap tests, HPV knowledge, and perceived barriers to gynecological 
care. Each participant received a $25 gift card at the time of interview as compensation for 
their time. This study was approved by the University of Kentucky Institutional Review 
Board.
Testing for HPV
The Hybrid Capture® 2 High-Risk HPV DNA Test® (Qiagen Corporation; Gaithersburg, 
MD)was used for the study. This test provides confirmation of the presence of one or more 
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of 13 high-risk types of HPV infection (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68). Women were verbally instructed by the nurse on the correct method for self-collecting a 
cervico-vaginal specimen. In addition, participants were given a graphic-based instruction 
sheet for use in the clinic restroom during the self-collection process. Women were 
instructed to insert a Fisherbrand* Cervex-Brush* Cervical Cell Sampler (Thermo Fisher 
Scientific Inc.; Waltham, MA) into the cervico-vaginal canal much like a tampon, until 
meeting resistance, rotate the brush five times, remove it slowly, and place it in the screw-
top vial containing Scope® mouth-wash. Specimens were labeled and sent to a laboratory 
(Cleveland Clinic Laboratories; Cleveland, OH) for analysis. All women were notified of 
their test results in person or by telephone by the nurse within 24 h of receiving the results 
from the laboratory.
Patient counseling and navigation
At the time of results notification, regardless of their HPV test results status, women were 
counseled on the importance of receiving routine, guideline-appropriate cervical cancer 
screening according to the U.S. Preventive Services Task Force's recommendations [33]. 
Additionally, all women were offered navigation services from the APRN, including help 
scheduling a Pap test at a local health department and assistance with transportation, 
childcare, and personal support if needed.
Lastly, the APRN conducted follow-up interviews two months post-results notification with 
all study participants to answer any additional questions about their results, inquire about 
whether or not they discussed their HPV test results with friends, family members, and/or 
sex partner(s), and ascertain whether or not a subsequent Pap test appointment had been 
made (and results if applicable).
Results
During recruitment for this pilot study, a total of 31 women were approached and recruited 
to participate. None of the women approached for participation declined, and all 
successfully completed the self-collected cervico-vaginal brush, indicating a 100% 
acceptance rate of this new high-risk HPV screening method among this sample of 
Appalachian Kentucky women (Fig. 1). As presented in Table 1, the mean age of the sample 
was 38.5 years (SD = 7.6). All participants self-identified as Caucasian. More than three-
quarters (77.4%) of the women reported an annual household income of <$25,000 and 40% 
did not have health insurance. Just over half of the women (58.1%) were married at the time 
of the baseline interview. Most women reported current cigarette smoking (73.3%). The 
mean number of lifetime male sex partners was 7.06 (SD = 5.6); five participants (16.7%) 
indicated that a male partner may have had concurrent sex with another partner during their 
time together. Three women (9.7%) reported never having a Pap test in their lifetime. 
Among those reporting at least one Pap test, six (19.4%) indicated having at least one 
abnormal result. Almost 90% of the women knew that cervical cancer is caused by HPV. 
Thirty percent of the sample indicated that they had minimal trust in doctors and the 
healthcare system, and that they did not have time to see a gynecologist. Forty percent of the 
women were “very afraid” of developing cervical cancer.
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Of the 31 women providing self-collected specimens, five (16.1%) tested positive for one of 
thirteen types of high-risk HPV types. None of the specimens yielded indeterminate 
findings, thereby suggesting that women used the proper technique for self-collection. None 
of the measures assessed in the self-administered questionnaire approached significance in 
testing possible associations with a high-risk HPV-positive result. Being single (P = .58), 
suspecting that a sex partner had concurrent partners (P = 1.00), ever having an abnormal 
Pap (P = .24), and current use of tobacco (P = .61) each yielded weak differences between 
groups. All five women testing positive for high-risk HPV reported a history of Pap testing; 
two of these women specifically reported a history of an abnormal Pap.
In assessing the impact of the patient counseling and navigation process which was identical 
for all study participants, at results notification, all 26 women testing negative for high-risk 
HPV declined nurse-assisted navigation to follow-up Pap testing. In contrast, four of the five 
women testing positive for high-risk HPV accepted navigation to the local health department 
for follow-up Pap testing. The fifth positive woman was lost to follow-up due to 
incarceration. All four women's follow-up Pap tests were normal as confirmed through 
medical record review.
Twenty-six of the 31 women (83.9%) were interviewed two months post-results notification; 
five women were lost to follow-up. Overall, women were more likely to discuss their HPV 
results with a family member (n = 15) than a sex partner (n = 6) or a female friend (n = 7). 
Even though all of the women testing negative for high-risk HPV initially declined 
navigation to Pap testing, at the two-month follow-up, two of these women had received a 
Pap test (with normal results) and nine indicated they were planning to make a future 
appointment.
Discussion
This novel, exploratory study found 100% acceptance of self-collecting cervico-vaginal 
specimens for HPV testing among a high-risk population of medically underserved women 
in Appalachian Kentucky. This acceptance rate is higher than previous studies examining 
acceptability of self-collected methods in rural regions of the U.S. [30,34,35]. We believe 
we had a higher acceptance rate for several reasons. First, we perceive women found self-
collection to be a favorable alternative to provider-performed Pap test due to its 
convenience, ease, privacy, brevity, and less invasive nature. Second, these women were 
attending a trusted healthcare clinic which provides many services for free or low-cost. In 
turn, women may have been more amenable to receiving a free health screening through our 
research study. Third, at the time of this study, the clinic did not offer Pap testing (patients 
were referred to the local health department); simultaneously, the women were also aware 
they were overdue for traditional Pap testing. Therefore, our “real time” offer of cervical 
cancer screening in the clinic – albeit with an alternative method – may have served as the 
tipping point for participation. Fourth, the APRN is indigenous to the community, living 
there all of her life. She is a trusted healthcare provider in the area and relates well to 
community members. Last, several of the women who participated in the study during the 
first few days of recruitment encouraged family members (e.g., mother-daughter, sister-
sister), coworkers, and other acquaintances to participate due to their own favorable 
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experience with the self-collection procedure and knowledge that their peers were also 
overdue for this important cancer screening test.
In the current study, approximately one of every six women (16.7%) tested positive for at 
least one high-risk type of HPV. Nationally, the prevalence of high-risk HPV infection for 
women ages 14–59 is 29% [36]. Importantly, a majority of the participants reported current 
cigarette use (73.3%). Tobacco use is known to be associated with a higher risk of cervical 
cancer among HPV-positive women [37] and noncompliance with Pap testing [12,38,39]; 
thus, women who use tobacco heighten their risk for ICC.
The navigation component of this study found that women are generally willing to receive a 
Pap test (or make a future appointment) after being informed of their HPV status and 
receiving counseling on the importance of guideline-appropriate cervical cancer screening. 
Interestingly, acceptance of nurse navigation was higher among those testing positive for 
high-risk HPV than those who tested negative in our relatively small sample. Women with 
positive results may perceive themselves at higher risk for ICC and thus be more likely to 
engage in protective behaviors such as Pap testing. These results are promising in that a 
recent study found that women who utilize a patient navigator typically have higher 
resolution rates (i.e., determination of a benign or malignant condition) within the first six 
months of an abnormal cervical screening, including ICC [40].
Clearly, this pilot study provides the impetus for larger scale studies of cervico-vaginal self-
brush collection for HPV testing among high-risk, medically underserved women in rural 
communities. Given the cultural, socioeconomic, and healthcare barriers associated with 
lower Pap testing rates among rural women, these initial findings suggest that self-collected 
brush screenings may be useful for this population as an initial screening, as has been 
previously established in other low-resource areas. If HPV self-collection were to gain 
approval for screening in the U.S. in the future, this would allow for focused triage of high-
risk HPV-positive women into follow-up Pap smear screening. Following screening 
guidelines, HPV-negative women would be able to extend their screening intervals to 3–5 
years depending on age and previous cervical cancer screening results [33]. Although none 
of the high-risk HPV-positive women in our study who had subsequent Pap smears were 
found to have abnormal cytology, it is likely that a greater number of cases would be 
identified in the application of this two-stage screening method (self-collection followed by 
Pap smear testing) in a larger sample or in clinical practice over time. Even a small number 
of high-grade cervical intraepithelial neoplasia (CIN) case findings would be likely to 
provide substantial cost-savings given the advantages of early detection and associated 
treatment. Indeed, potential discovery of cervical abnormalities following a positive high-
risk HPV test via self-collection could help lessen the $1.2 billion direct [and $1.8 billion 
indirect] medical costs associated with treating cervical abnormalities and malignancies each 
year in the U.S. [41,42].
Noted limitations to this pilot study include the small sample size and use of a convenience 
sample. The study sample was also limited in racial and ethnic diversity, reflecting the 
composition of the Appalachian Kentucky population. Therefore, the results may not be 
generalizable to all rural or Appalachian populations. Results of the Hybrid Capture® 2 
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High-Risk HPV DNA Test® only provide confirmation of one or more of 13 high-risk types 
of HPV. Assay results do not confirm the presence of low-risk HPV types such as 6 or 11 
known to cause genital warts, nor do they confirm negative HPV infection. Additionally, the 
data collected via baseline and follow-up interviews were primarily based on self-report. 
Previous studies have noted that women tend to overstate their participation in cervical 
cancer screenings [43]. There is also the possibility for selection bias as study participants 
were already seeking services at a healthcare clinic and may be more proactive in accepting 
cervical cancer screening. However, despite a clinic-based setting, all 31 women verbally 
confirmed they were overdue for routine cervical cancer screening by at least four years, 
though we did not assess the exact number of years they were overdue. The study design 
also did not allow for a comparison of acceptance rates with women who were guideline-
compliant with cervical cancer screening. Lastly, we did not directly assess the women's 
experience with self-collection via survey or indepth qualitative inquiry. However, the 
APRN received anecdotal comments indicating a favorable experience with the self-
collection process and preference over a traditional, provider-performed Pap test. Several 
women inquired about the possibility of performing the self-collection strategy annually in 
their own homes.
Despite these limitations, our study tested a two-stage process – self-collection for HPV 
testing, followed by patient navigation to clinical services – which focused on eliminating 
barriers to cervical cancer screening among an at-risk population of women in a medically 
underserved, rural region of Kentucky. Women in this area are disproportionately burdened 
by cervical cancer incidence and mortality compared to women in non-Appalachian 
Kentucky and other regions of the U.S. The well-documented barriers to cervical cancer 
screening among rural women necessitate creative and efficacious solutions. Consequently, 
tailoring alternative cancer screening strategies to meet the complex needs of medically 
underserved rural women is likely to lead to reductions in incidence, morbidity, and 
mortality rates of cervical cancer and related medical costs among this vulnerable 
population.
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Table 1
Participant characteristics (N = 31).
Characteristic N (%)
Age (years)
  Mean (SD) 38.5 (7.6)
  Range 29–58
Race/ethnicity
  Caucasian 31 (100)
Income
  <$25,000 24 (77.4)
  >$25,000 7 (22.6)
Health insurance (n = 30)
  Yes 17 (56.7)
  No 13 (43.3)
Marital status
  Single 8 (25.8)
  Married 18 (58.1)
  Separated/divorced/widowed 5 (16.1)
Current cigarette use (n = 30)
  Yes 22 (73.3)
  No 8 (26.7)
Lifetime male sex partners (number)
  Mean (SD) 7.06 (5.6)
  Range 0–20
Past 12 months male sex partners (number)
  Mean (SD) 1.13 (.56)
  Range 0–3
Sex with male who had concurrent partners (n = 30)
  Yes 5 (16.7)
  No 26 (83.3)
Ever had a Pap smear
  Yes 28 (90.3)
  No 3 (9.7)
Cervical cancer knowledge and perceived barriers to gynecological care
  Cervical cancer is caused by HPV 27 (87.1)
  Some or very little trust in doctors and healthcare system (n = 30) 9 (30.0)
  No time to visit a gynecologist 9 (29.0)
  Very afraid of developing cervical cancer 12 (38.7)
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